{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T22:00:25Z","timestamp":1777068025925,"version":"3.51.4"},"reference-count":30,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive subjects with various macular diseases that received six or more of 0.05\u2009mL IVZ (1.25\u2009mg) injections with at least 1\u2009year follow-up were included. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>107 eyes of 91 subjects received IVZ and were followed with mean\u00b1SD\u2009follow-up interval of 1.48\u00b10.44 months following treat and extend or pro-re-nata protocol. The distribution included neovascular macular degeneration (42 eyes), diabetic macular oedema (32 eyes) and macular oedema secondary to retinal vein occlusion (11 eyes). Fifty eyes were naive, while 57 eyes were previously treated. Combining all disease categories, CMT decreased significantly by 133.0\u00b1153.0\u2009\u00b5m at the 24-month follow-up (P&lt;0.001) with BCVA gain of 0.35\u00b10.37 at the 24-month follow-up (P&lt;0.001) with mean number of injections of 8.5 at month 12, 2.4 between 12 and 18\u2009month and 1.7 between 18 and 24\u2009month. Ocular and systemic adverse effects included one episode of transient uveitis and one instance of central retinal artery occlusion after 1121 injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IVZ appears safe and efficacious in the therapy of macular diseases through 2\u2009years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-311591","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T12:16:12Z","timestamp":1515500172000},"page":"1387-1390","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Two-year outcomes of intravitreal ziv-aflibercept"],"prefix":"10.1136","volume":"102","author":[{"given":"Ahmad M","family":"Mansour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4231-2566","authenticated-orcid":false,"given":"Mohammed","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrazzak","family":"Charbaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad H","family":"Younis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-704X","authenticated-orcid":false,"given":"Ahmed A","family":"Souka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avantika","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana A","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"key":"2023012305101345000_102.10.1387.1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20141118-15"},{"key":"2023012305101345000_102.10.1387.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305302"},{"key":"2023012305101345000_102.10.1387.3","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20150101-17"},{"key":"2023012305101345000_102.10.1387.4","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-306319"},{"key":"2023012305101345000_102.10.1387.5","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/IAE.0000000000001000","article-title":"Intravitreal injections of ziv-aflibercept for diabetic macular edema: a pilot study","volume":"36","author":"Andrade","year":"2016","journal-title":"Retina"},{"key":"2023012305101345000_102.10.1387.6","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-308319"},{"key":"2023012305101345000_102.10.1387.7","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308679"},{"key":"2023012305101345000_102.10.1387.8","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/OPTH.S116343","article-title":"Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion","volume":"10","author":"Paulose","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"2023012305101345000_102.10.1387.9","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/IAE.0000000000001440","article-title":"Short-term safety of 2 mg intravitreal ziv-aflibercept","volume":"37","author":"Chhablani","year":"2017","journal-title":"Retina"},{"key":"2023012305101345000_102.10.1387.10","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1111\/aos.13352","article-title":"Comparison between the short-term outcomes of bevacizumab and ziv-aflibercept in the treatment of primary diabetic macular oedema","volume":"95","author":"Ashraf","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"2023012305101345000_102.10.1387.11","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309994"},{"key":"2023012305101345000_102.10.1387.12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3928\/23258160-20170428-06","article-title":"Safety and Efficacy of ziv-aflibercept in the Treatment of Refractory Diabetic Macular Edema","volume":"48","author":"Ashraf","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2023012305101345000_102.10.1387.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309724"},{"key":"2023012305101345000_102.10.1387.14","doi-asserted-by":"crossref","unstructured":"Chan EW , Eldeeb M , Dedhia CJ , et al . One-year treatment outcomes of ziv-aflibercept for treatment-na\u00efve macular oedema in branch retinal vein occlusion. Acta Ophthalmol 2017.doi:10.1111\/aos.13432","DOI":"10.1111\/aos.13432"},{"key":"2023012305101345000_102.10.1387.15","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/IAE.0000000000001385","article-title":"Clinical and electrophysiological evaluation after intravitreal ziv-aflibercept for exudative age-related macular degeneration","volume":"37","author":"de Oliveira Dias","year":"2017","journal-title":"Retina"},{"key":"2023012305101345000_102.10.1387.16","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-212988"},{"key":"2023012305101345000_102.10.1387.17","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.159909"},{"key":"2023012305101345000_102.10.1387.18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40942-016-0026-y","article-title":"Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept","volume":"2","author":"de Oliveira Dias","year":"2016","journal-title":"Int J Retina Vitreous"},{"key":"2023012305101345000_102.10.1387.19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.oret.2016.08.007","article-title":"Two doses of intravitreal ziv-aflibercept versus bevacizumab in treatment of diabetic macular edema: a three-armed, double-blind randomized trial","volume":"1","author":"Baghi","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"2023012305101345000_102.10.1387.20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000452677","article-title":"Viability of primary human pigment epithelium cells and muller-glia cells after intravitreal ziv-aflibercept and aflibercept","volume":"236","author":"Costa de Andrade","year":"2016","journal-title":"Ophthalmologica"},{"key":"2023012305101345000_102.10.1387.21","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/ICO.0000000000001251","article-title":"Regression of Inflamed Pterygia by Frequent High-Dose Intralesional Ziv-Aflibercept","volume":"36","author":"Mansour","year":"2017","journal-title":"Cornea"},{"key":"2023012305101345000_102.10.1387.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"2023012305101345000_102.10.1387.23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.oret.2017.01.004","article-title":"Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration","volume":"1","author":"Kaiser","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"2023012305101345000_102.10.1387.24","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2023012305101345000_102.10.1387.25","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20150101-10"},{"key":"2023012305101345000_102.10.1387.26","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s00417-014-2641-3","article-title":"The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters","volume":"252","author":"Elshout","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2023012305101345000_102.10.1387.27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jcjo.2016.11.012","article-title":"Long-term in vitro functional stability of compounded ranibizumab and aflibercept","volume":"52","author":"Cao","year":"2017","journal-title":"Can J Ophthalmol"},{"key":"2023012305101345000_102.10.1387.28","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/eye.2015.28","article-title":"Storage stability of bevacizumab in polycarbonate and polypropylene syringes","volume":"29","author":"Khalili","year":"2015","journal-title":"Eye"},{"key":"2023012305101345000_102.10.1387.29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaophthalmol.2014.5650","article-title":"Postmarketing analysis of aflibercept-related sterile intraocular inflammation","volume":"133","author":"Hahn","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2023012305101345000_102.10.1387.30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/OPTH.S29075","article-title":"Insight into 144 patients with ocular vascular events during VEGF antagonist injections","volume":"6","author":"Mansour","year":"2012","journal-title":"Clin Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-311591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T08:14:26Z","timestamp":1674461666000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-311591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,9,24]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1136\/bjophthalmol-2017-311591"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311591","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732442750.793563443","asserted-by":"object"}]},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,9]]}}}